| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.34 | 5e-14 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.22 | 7e-10 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.2 | 2e-08 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-07 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.15 | 3e-07 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.12 | 2e-05 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.21 | 3e-05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |